Breaking News

NHTSA Had ‘Ample Information’ to Find GM Ignition Switch Defect: Report
Tweet TWEET

Amarin, Celgene, GlaxoSmithKline, Spectrum Pharma, and Geron Briefing and Review

  Amarin, Celgene, GlaxoSmithKline, Spectrum Pharma, and Geron Briefing and
                                    Review

PR Newswire

LONDON, March 18, 2013

LONDON, March 18, 2013 /PRNewswire/ --

The healthcare industry is evaluating the impact of President Obama's
Affordable Care Act (ACA) on their businesses. While critics of the healthcare
reform say that the ACA will result in higher costs for healthcare companies,
supporters of the reform point out the long-term benefits to the industry
which include players such as Amarin Corporation Plc (NASDAQ: AMRN), Celgene
Corporation (NASDAQ: CELG), GlaxoSmithKline Plc (NYSE: GSK), Spectrum
Pharmaceuticals Inc. (NASDAQ: SPPI) and Geron Corporation (NASDAQ: GERN). On
Friday, healthcare stocks ended mostly lower, tracking losses in the broad
market. StockCall has released free charting and technical research on these
aforementioned companies. Register to read these reports at

http://www.stockcall.com/report 

Shares of Amarin Corporation Plc edged higher in Friday's trading session even
as the broad market struggled. The stock closed 0.83% higher at $8.46 on
volume of 2.40 million. Despite Friday's gains, Amarin's shares have fallen
2.08%. Year-to-date, the company's shares have gained more than 4.50%. The
stock has just crossed its 50-day moving average, which is a bullish signal.
The bullish trend is further confirmed by the MACD chart. The stock's MACD has
just moved above the zero-line. Sign up for the free report on AMRN at

http://www.StockCall.com/AMRN031813.pdf 

Celgene Corporation shares fell sharply in trading on Friday. The stock closed
1.65% lower at $112.40 on above average volume of 4.97 million, paring most of
the gains for the week. Still, the stock managed to finish almost 1% higher
for the week. Celgence's shares have seen a series of highs over the last two
weeks, which is a bullish signal. The positive trend is further confirmed by
recent volume activity. However, the stock's MACD chart suggests that the
upbeat trend may have come to an end. CELG free technical report can be
accessed by signing up at

http://www.StockCall.com/CELG031813.pdf 

Shares of U.K.-based pharmaceutical giant, GlaxoSmithKline Plc edged higher in
trading on the previous week's last day trading session, extending its gains
for the week. The stock finished 0.18% higher at $45.30 on volume of 1.99
million, taking its gains for the week to over 1.60%. GlaxoSmithKline's shares
are facing stiff resistance at around $45.50. The stock has struggled to break
through this level recently. The stock's MACD has just crossed above the
signal line, which is a strong bullish signal. This optimistic trend is
further confirmed by the volume activity in the last 10 sessions. Free report
on GSK can be accessed by registering at

http://www.StockCall.com/GSK031813.pdf 

Spectrum Pharmaceuticals Inc. shares have fallen sharply so far in 2013.
Year-to-date, shares of the biotechnology company are down more than 30%,
mainly due to the significant losses posted last week. Spectrum's shares fell
more than 34% last week. On Friday, the stock once again struggled, falling
0.64% to finish the day at $7.76 on above average volume of 2.65 million. The
company's shares have fallen below some key technical levels as a result of
the sell-off last week. Register with StockCall and download the research on
SPPI for free at

http://www.StockCall.com/SPPI031813.pdf

Shares of Geron Corporation tumbled in Friday's trading session, ending 9.60%
lower at $1.13 on above average volume of 2.89 million. The stock has now
fallen more than 20% in the last three sessions. For the year, the stock is
now down nearly 20%, mainly due to the losses seen a week ago. Geron's shares
have fallen below $1.20 support level. The stock's MACD has also slipped below
the signal line, which is a strong bearish signal. Read the full free research
on GERN by signing up to StockCall at

http://www.StockCall.com/GERN031813.pdf 

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com 

SOURCE StockCall.com

Contact: Contact Person: William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
 
Press spacebar to pause and continue. Press esc to stop.